VRCA - NASDAQ
Verrica Pharmaceuticals Inc.
$6.15
+7.5%Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
At a Glance
Live Snapshotvrca
Total Liabilities and Equity
Last Annual Value
47.13M
3-Year CAGR
2%
5-Year CAGR
-9%
10-Year CAGR
56%
Verrica Pharmaceuticals Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Verrica Pharmaceuticals Inc. NASDAQ:VRCA | 47.13M | -16.7% | -10.1% | 56.2% | |
 Q32 Bio Inc. NASDAQ:QTTB | 61.78M | 9.5% | -21.8% | 15.8% | |
 AN2 Therapeutics, Inc. NASDAQ:ANTX | 61.95M | -23.6% | -1.1% | N/A |
Verrica Pharmaceuticals Inc. Fair Value Envelope
Related Guides
Continue your VRCA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.